Serina Therapeutics (SER) Stock: Buy, Sell, or Hold?
SER - Serina Therapeutics, Inc.
$1.65
-0.07 (-4.07%)
▼
5d:
-14.95%
30d:
-26.67%
90d:
-21.05%
WAIT
LOW Confidence
Analysis Updated: Oct 16, 2026 12:00 AM ET
Earnings: Nov 12, 2026
23d
Get Alerted When SER Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: SER is down 14.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: SER is down 14.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: SER is currently trading at $1.65, which is considered oversold relative to its 30-day fair value range of $1.86 to $2.28.
Technical Outlook: Technically, SER is in a strong downtrend. The price is currently testing key support at $1.65. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: SER scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $9.50 (+452.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SER is in a strong downtrend. The price is currently testing key support at $1.65. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: SER scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $9.50 (+452.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.86 -
$2.28
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.1%)
- BULLISH: Trading 452.3% below Wall St target ($9.50)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.86 -
$2.28
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.65
Resistance Level
$2.08
Current Trend
Strong Downtrend
Technical data as of
Oct 19, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.49
Wall Street Target
$9.50
(+452.3%)
Revenue Growth (YoY)
154.9%
Earnings Growth (YoY)
-43.5%
Share & Embed Analysis
Last updated: October 19, 2026 3:57 PM ET
Data refreshes hourly during market hours. Next update: 4:57 PM
Data refreshes hourly during market hours. Next update: 4:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SER showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 55 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 54 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 44 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 58 HOLD |
|
STOK
Stoke Therapeutics Inc |
STRONG BUY
14 analysts |
$46 | 74 BUY |
